课题基金 / 基金详情

TOLERANCE, SAFETY AND ACTIVITY OF RIFAPENTINE ALONE AND IN COMBINATION/ AIDS

TOLERANCE, SAFETY AND ACTIVITY OF RIFAPENTINE ALONE AND IN COMBINATION/ AIDS
利福喷汀单药及联合用药/艾滋病的耐受性、安全性和活性
批准号：
6275247
负责人：
KENT SEPKOWITZ
金额：
$5.51万
依托单位：
WEILL MEDICAL COLL OF CORNELL UNIV
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1998-11-30
来源：
https://reporter.nih.gov/project-details/6275247
关键词：
AIDS therapy Mycobacterium avium antibiotics azithromycin clarithromycin clinical research combination chemotherapy drug screening /evaluation human subject human therapy evaluation rifamycins

项目摘要

项目成果

KENT SEPKOWITZ的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Phase II study of the safety, tolerability and activity of rifapentine, a new rifamycin compound, when used in combination with azithromycin, clarithromycin, or ethambutol for the treatment of Mycobacterium Avium Complex Bacteremia in patients with AIDS. Rifapentine has shown excellent in vitro activity against MAC, and has shown a more favorable toxicity profile in early studies.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Clinical Research and Mentoring in Infectious Disease
Clinical Research and Mentoring in Infectious Disease
Clinical Research and Mentoring in Infectious Disease
Clinical Research and Mentoring in Infectious Disease
海外基金